Reply Letter

Reply: Sex-Based Differences in Outcomes of Oral Anticoagulation: Does the Antiplatelet Therapy Matter?

Sharon W. Y. Law, MPharm,a Wallis C. Y. Lau, PhD,a,b Ian C. K. Wong, PhD,a,b Esther W. Chan, PhDa

From the aCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; and bResearch Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom

Disclosures:

Dr. Wong has received research funding from Research Grants Council of the University Grants Committee in the Hong Kong Special Administrative Region, Narcotics Division of the Security Bureau of The Government of the Hong Kong Special Administrative Region, Research Fund Secretariat of the Food and Health Bureau of The Government of the Hong Kong Special Administrative Region, Bristol-Myers Squibb, Pfizer, and Janssen for work unrelated to the study. Dr. Chan has received research funding from Research Grants Council of the University Grants Committee in the Hong Kong Special Administrative Region, Narcotics Division of the Security Bureau of The Government of the Hong Kong Special Administrative Region, Research Fund Secretariat of the Food and Health Bureau of The Government of the Hong Kong Special Administrative Region, Bristol-Myers Squibb, Pfizer, and Janssen for work unrelated to the study. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Address for Correspondence:

Dr. Esther W. Chan
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Office 02-08, 2/F Laboratory Block, 21 Sassoon Road, Hong Kong SAR, China
Telephone: +852 2831 5110
Fax: +852 2817 0859
Email: ewchan@hku.hk
We thank Dr. Mo and colleagues for their interest in our study and the opportunity for a discussion on the possible confounding of the sex-based differences in the risk of intracranial hemorrhage. First, we agree that the use of an antiplatelet may affect treatment outcomes and treatment choices between direct oral anticoagulants (DOACs) and warfarin (1). Over 70% of the patients in our study were treated with an antiplatelet within 90 days on or before the index date, which was defined as the start date of the first prescription of oral anticoagulants. To reduce confounding, antiplatelet was included in our propensity score model and the baseline characteristics between the comparison groups were well balanced with standardized differences less than 0.1 in both men and women. Although it was suggested in a previous study that high platelet reactivity was associated with a reduced risk of bleeding in women only, it was a post hoc analysis in which the target patient group and definition of bleeding outcomes were different from our study (2). Of note, the objective of our study was to compare the clinical outcomes of DOACs versus warfarin within men and within women, respectively. Further investigation into the understanding on the effect of antiplatelets on the clinical outcomes of DOACs versus warfarin in the specific sex is warranted.

Second, the aim of our study was to provide more evidence to inform the choice of oral anticoagulants within a specific sex. We concluded that DOACs were associated with a lower risk of intracranial hemorrhage and all-cause mortality in women only. Propensity score matching was performed between DOAC and warfarin groups, but not between men and
women. A different methodology will be required to balance any differences in baseline characteristics, including the CHA$_2$DS$_2$-VASc score, between sexes. This is a different study objective and beyond the scope of the current study. Further comparisons with a larger sample size are required to investigate the association between sex and intracranial hemorrhage within the specific oral anticoagulant.

References:
